These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 30973663)

  • 1. Epidermal growth factor receptor-targeted molecular imaging of colorectal tumors: Detection and treatment evaluation of tumors in animal models.
    Miyamoto Y; Muguruma N; Fujimoto S; Okada Y; Kida Y; Nakamura F; Tanaka K; Nakagawa T; Kitamura S; Okamoto K; Miyamoto H; Sato Y; Takayama T
    Cancer Sci; 2019 Jun; 110(6):1921-1930. PubMed ID: 30973663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation of a novel EGFR specific immunotoxin and its efficacy of anti-colorectal cancer in vitro and in vivo.
    Wu S; Deng C; Zhang C; Xiong J; Gu X; Wang Z; Tu J; Xie J
    Clin Transl Oncol; 2021 Aug; 23(8):1549-1560. PubMed ID: 33474678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo molecular imaging with cetuximab, an anti-EGFR antibody, for prediction of response in xenograft models of human colorectal cancer.
    Goetz M; Hoetker MS; Diken M; Galle PR; Kiesslich R
    Endoscopy; 2013 Jun; 45(6):469-77. PubMed ID: 23580409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular Uptake and Cytotoxic Effect of Epidermal Growth Factor Receptor Targeted and Plitidepsin Loaded Co-Polymeric Polymersomes on Colorectal Cancer Cell Lines.
    Goñi-de-Cerio F; Thevenot J; Oliveira H; Pérez-Andrés E; Berra E; Masa M; Suárez-Merino B; Lecommandoux S; Heredia P
    J Biomed Nanotechnol; 2015 Nov; 11(11):2034-49. PubMed ID: 26554161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model.
    Ding C; Li L; Yang T; Fan X; Wu G
    BMC Cancer; 2016 Oct; 16(1):791. PubMed ID: 27729020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models.
    Vangala D; Ladigan S; Liffers ST; Noseir S; Maghnouj A; Götze TM; Verdoodt B; Klein-Scory S; Godfrey L; Zowada MK; Huerta M; Edelstein DL; de Villarreal JM; Marqués M; Kumbrink J; Jung A; Schiergens T; Werner J; Heinemann V; Stintzing S; Lindoerfer D; Mansmann U; Pohl M; Teschendorf C; Bernhardt C; Wolters H; Stern J; Usta S; Viebahn R; Admard J; Casadei N; Fröhling S; Ball CR; Siveke JT; Glimm H; Tannapfel A; Schmiegel W; Hahn SA
    Genome Med; 2021 Jul; 13(1):116. PubMed ID: 34271981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Panitumumab-IRDye800CW for Fluorescence-Guided Surgical Resection of Colorectal Cancer.
    Marston JC; Kennedy GD; Lapi SE; Hartman YE; Richardson MT; Modi HM; Warram JM
    J Surg Res; 2019 Jul; 239():44-51. PubMed ID: 30798171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo molecular imaging of colorectal cancer with confocal endomicroscopy by targeting epidermal growth factor receptor.
    Goetz M; Ziebart A; Foersch S; Vieth M; Waldner MJ; Delaney P; Galle PR; Neurath MF; Kiesslich R
    Gastroenterology; 2010 Feb; 138(2):435-46. PubMed ID: 19852961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer.
    Geißler AL; Geißler M; Kottmann D; Lutz L; Fichter CD; Fritsch R; Weddeling B; Makowiec F; Werner M; Lassmann S
    Oncotarget; 2017 Mar; 8(10):17164-17190. PubMed ID: 28199979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular imaging of therapeutic response to epidermal growth factor receptor blockade in colorectal cancer.
    Manning HC; Merchant NB; Foutch AC; Virostko JM; Wyatt SK; Shah C; McKinley ET; Xie J; Mutic NJ; Washington MK; LaFleur B; Tantawy MN; Peterson TE; Ansari MS; Baldwin RM; Rothenberg ML; Bornhop DJ; Gore JC; Coffey RJ
    Clin Cancer Res; 2008 Nov; 14(22):7413-22. PubMed ID: 19010858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of FGF9 gene in resistance to anti-EGFR therapies targeting colorectal cancer: A subset of colorectal cancer patients with FGF9 upregulation may be resistant to anti-EGFR therapies.
    Mizukami T; Togashi Y; Naruki S; Banno E; Terashima M; de Velasco MA; Sakai K; Yoneshige A; Hayashi H; Fujita Y; Tomida S; Nakajima TE; Fujino T; Boku N; Ito A; Nakagawa K; Nishio K
    Mol Carcinog; 2017 Jan; 56(1):106-117. PubMed ID: 26916220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.
    Tang Z; Yuan X; Du R; Cheung SH; Zhang G; Wei J; Zhao Y; Feng Y; Peng H; Zhang Y; Du Y; Hu X; Gong W; Liu Y; Gao Y; Liu Y; Hao R; Li S; Wang S; Ji J; Zhang L; Li S; Sutton D; Wei M; Zhou C; Wang L; Luo L
    Mol Cancer Ther; 2015 Oct; 14(10):2187-97. PubMed ID: 26208524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Colorectal adenocarcinoma-derived EGFR mutants are oncogenic and sensitive to EGFR-targeted monoclonal antibodies, cetuximab and panitumumab.
    Kim N; Cho D; Kim H; Kim S; Cha YJ; Greulich H; Bass A; Cho HS; Cho J
    Int J Cancer; 2020 Apr; 146(8):2194-2200. PubMed ID: 31290142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of EGFR-targeted evodiamine nanoparticles for the treatment of colorectal cancer.
    Li C; Cai G; Song D; Gao R; Teng P; Zhou L; Ji Q; Sui H; Cai J; Li Q; Wang Y
    Biomater Sci; 2019 Aug; 7(9):3627-3639. PubMed ID: 31328737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Signal transduction pathways of the epidermal growth factor receptor in colorectal cancer and their inhibition by small molecules.
    Efferth T
    Curr Med Chem; 2012; 19(33):5735-44. PubMed ID: 23033949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deficient HER3 expression in poorly-differentiated colorectal cancer cells enhances gefitinib sensitivity.
    Nakata S; Tanaka H; Ito Y; Hara M; Fujita M; Kondo E; Kanemitsu Y; Yatabe Y; Nakanishi H
    Int J Oncol; 2014 Oct; 45(4):1583-93. PubMed ID: 25017791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [fam-] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification.
    Takegawa N; Tsurutani J; Kawakami H; Yonesaka K; Kato R; Haratani K; Hayashi H; Takeda M; Nonagase Y; Maenishi O; Nakagawa K
    Int J Cancer; 2019 Dec; 145(12):3414-3424. PubMed ID: 31087550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular subtypes of colorectal cancer in pre-clinical models show differential response to targeted therapies: Treatment implications beyond KRAS mutations.
    Pal R; Wei N; Song N; Wu S; Kim RS; Wang Y; Gavin PG; Lucas PC; Srinivasan A; Allegra CJ; Jacobs SA; Paik S; Schmitz JC; Pogue-Geile KL
    PLoS One; 2018; 13(8):e0200836. PubMed ID: 30118499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous inhibition of IGF1R and EGFR enhances the efficacy of standard treatment for colorectal cancer by the impairment of DNA repair and the induction of cell death.
    Oberthür R; Seemann H; Gehrig J; Rave-Fränk M; Bremmer F; Halpape R; Conradi LC; Scharf JG; Burfeind P; Kaulfuß S
    Cancer Lett; 2017 Oct; 407():93-105. PubMed ID: 28823963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A human IgG-like bispecific antibody co-targeting epidermal growth factor receptor and the vascular endothelial growth factor receptor 2 for enhanced antitumor activity.
    Chen Z; Xie W; Acheampong DO; Xu M; He H; Yang M; Li C; Luo C; Wang M; Zhang J
    Cancer Biol Ther; 2016; 17(2):139-50. PubMed ID: 26671532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.